Related references
Note: Only part of the references are listed.Immunization with the DNA-Encoding N-Terminal Domain of Proteophosphoglycan of Leishmania donovani Generates Th1-Type Immunoprotective Response against Experimental Visceral Leishmaniasis
Mukesh Samant et al.
JOURNAL OF IMMUNOLOGY (2009)
Pathogenic role of B cells and antibodies in murine Leishmania amazonensis infection
Nanchaya Wanasen et al.
INTERNATIONAL JOURNAL FOR PARASITOLOGY (2008)
Proteomic approaches for discovery & new targets for vaccine and therapeutics against visceral leishmaniasis
Shraddha Kumari et al.
PROTEOMICS CLINICAL APPLICATIONS (2008)
Induction of Th1-type cellular responses in cured/exposed Leishmania-infected patients and hamsters against polyproteins of soluble Leishmania donovani promastigotes ranging from 89.9 to 97.1 kDa
Shraddha Kumari et al.
VACCINE (2008)
Cysteine proteinase type III is protective against Leishmania infantum infection in BALB/c mice and highly antigenic in visceral leishmaniasis individuals
Naghmeh Khoshgoo et al.
VACCINE (2008)
Protective immunity against challenge with Leishmania (Leishmania) chagasi in beagle dogs vaccinated with recombinant A2 protein
Ana Paula Fernandes et al.
VACCINE (2008)
Leishmanial antigens in liposomes promote protective immunity and provide immunotherapy against visceral leishmaniasis via polarized Th1 response
Sudipta Bhowmick et al.
VACCINE (2007)
Proteomic approach for identification and characterization of novel immunostimulatory proteins from soluble antigens of Leishmania donovani promastigotes
Shraddha Kumari Gupta et al.
PROTEOMICS (2007)
Immune response and protection assay of recombinant major surface glycoprotein of Leishmania (rgp63) reconstituted with liposomes in BALB/c mice
Mahmoud R. Jaafari et al.
VACCINE (2006)
Leishmania donovani:: Identification of stimulatory soluble antigenic proteins using cured human and hamster lymphocytes for their prophylactic potential against visceral leishmaniasis
R Garg et al.
VACCINE (2006)
Interactions among yeast protein-disulfide isomerase proteins and endoplasmic reticulum chaperone proteins influence their activities
T Kimura et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
A heterologous prime-boost vaccination regimen using ORFF DNA and recombinant ORFF protein confers protective immunity against experimental visceral leishmaniasis
P Tewary et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation:: Evidence for mixed Th1-and Th2-like responses in visceral leishmaniasis
R Basu et al.
JOURNAL OF IMMUNOLOGY (2005)
Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models
A Dube et al.
PARASITOLOGY RESEARCH (2005)
Immunostimulatory cellular responses of cured Leishmania-infected patients and hamsters against the integral membrane proteins and non-membranous soluble proteins of a recent clinical isolate of Leishmania donovani
R Garg et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2005)
A role for IgG immune complexes during infection with the intracellular pathogen Leishmania
SA Miles et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Safety, immunogenecity, and efficacy of an autoclaved Leishmania amazonensis vaccine plus BCG adjuvant against New World cutaneous leishmaniasis
RX Armijos et al.
VACCINE (2004)
Leishmaniasis: current situation and new perspectives
P Desjeux
COMPARATIVE IMMUNOLOGY MICROBIOLOGY AND INFECTIOUS DISEASES (2004)
Leishmania/HIV co-infections:: epidemiology in Europe
P Desjeux et al.
ANNALS OF TROPICAL MEDICINE AND PARASITOLOGY (2003)
Leishmania donovani resistance to miltefosine involves a defective inward translocation of the drug
FJ Pérez-Victoria et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
The relative contribution of IL-4 receptor signaling and IL-10 to susceptibility to Leishmania major
N Noben-Trauth et al.
JOURNAL OF IMMUNOLOGY (2003)
The in vivo susceptibility of Leishmania donovani to sodium stibogluconate is drug specific and can be reversed by inhibiting glutathione biosynthesis
KC Carter et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
An atypical protein disulfide isomerase from the protozoan parasite Leishmania containing a single thioredoxin-like domain
A Padilla et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Characterization of Leishmania donovani antigens encapsulated in liposomes that induce protective immunity in BALB/c mice
F Afrin et al.
INFECTION AND IMMUNITY (2002)
Protein disulfide isomerase of Toxoplasma gondii is targeted by mucosal IgA antibodies in humans
B Meek et al.
FEBS LETTERS (2002)
Identification of a disulfide isomerase protein of Leishmania major as a putative virulence factor
Y Ben Achour et al.
INFECTION AND IMMUNITY (2002)
Drug resistance in Indian visceral leishmaniasis
S Sundar
TROPICAL MEDICINE & INTERNATIONAL HEALTH (2001)
Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease
A Campos-Neto et al.
INFECTION AND IMMUNITY (2001)
The hamster as a model of human visceral leishmaniasis: Progressive disease and impaired generation of nitric oxide in the face of a prominent Th1-like cytokine response
PC Melby et al.
JOURNAL OF IMMUNOLOGY (2001)
Interleukin-12 regulates the response to chemotherapy in experimental visceral leishmaniasis.
HW Murray et al.
JOURNAL OF INFECTIOUS DISEASES (2000)
Share Paper
